StockNews.AI
EPIX
StockNews.AI
180 days

Investors who lost money on ESSA Pharma Inc.(EPIX) should contact The Gross Law Firm about pending Class Action - EPIX

1. Gross Law Firm launches class action against EPIX for misleading statements. 2. Allegations claim false efficacy claims regarding masofaniten with enzalutamide. 3. Shareholders urged to register for potential lead plaintiff roles before March 25, 2025. 4. Case centers on overstated clinical, regulatory, and commercial prospects in prostate cancer therapy.

4m saved
Insight
Article

FAQ

Why Bearish?

Lawsuit allegations of deceptive claims can reduce investor confidence and depress stock prices. Previous biotech cases facing legal challenges, such as class actions, have experienced sharp price declines upon news release.

How important is it?

The lawsuit could lead to significant legal liabilities and reputational risk, directly impacting stock valuation. The potential recovery amounts and litigation expenses make this news highly material for investor sentiment.

Why Short Term?

The immediate market reaction is likely driven by legal uncertainty and potential settlement risks, leading to near-term volatility. Historical examples show that such regulatory or legal news trigger sharp, short-term declines before any long-term resolution.

Related Companies

NEW YORK, Feb. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ESSA Pharma Inc. (NASDAQ: EPIX). Shareholders who purchased shares of EPIX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/essa-pharma-inc-loss-submission-form/?id=130529&from=4 CLASS PERIOD: December 12, 2023 to October 31, 2024 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) masofaniten in combination with enzalutamide had no clear efficacy benefit over enzalutamide alone; (ii) accordingly, masofaniten in combination with enzalutamide was less effective in treating prostate cancer than defendants had led investors to believe; (iii) the M-E Combination Study, a monotherapy and combination therapy for the treatment of prostate cancer, was unlikely to meet its prespecified Phase 2 primary endpoint; (iv) accordingly, defendants had overstated masofaniten's clinical, regulatory, and commercial prospects; and (v) as a result, defendants' public statements were materially false and misleading at all relevant times. DEADLINE: March 25, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/essa-pharma-inc-loss-submission-form/?id=130529&from=4 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of EPIX during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is March 25, 2025. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: [email protected] Phone: (646) 453-8903 SOURCE The Gross Law Firm

Related News